Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.
about
Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits.Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats.Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.Liposomal amphotericin B and leishmaniasis: dose and responseAntifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephrDistribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits.Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infectionsComparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits.Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholateComparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbitsOcular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis modelSelf-assembled amphotericin B-loaded polyglutamic acid nanoparticles: preparation, characterization and in vitro potential against Candida albicans.Carrier effects on biological activity of amphotericin B.Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimensLiposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.CNS pharmacokinetics of antifungal agents.High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic studyAntileishmanial activity, uptake, and biodistribution of an amphotericin B and poly(α-Glutamic Acid) complex.Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.Secondary Antifungal Prophylaxis in Hematopoietic Stem Cell Transplantation (HSCT)/Acute Leukemia Patients.The use of antifungal therapy in neonatal intensive care.Are salt loading and prolonging infusion period effective in prevention of amphotericin B-induced nephrotoxicity?Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Quantitation of slow drug release from an implantable and degradable gentamicin conjugate by in vivo magnetic resonance imagingAmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.Comparison of the effects of liposomal amphotericin B and conventional amphotericin B on propafenone metabolism and hepatic cytochrome P-450 in ratsA sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies.Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats.Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.Tissue pharmacokinetics and pharmacodynamics of AmBisome® (L-AmBis) in uninfected and infected animals and their effects on dosing regimens.Amphotericin B concentrations in healthy mallard ducks (Anas platyrhynchos) following a single intratracheal dose of liposomal amphotericin B using an atomizer.
P2860
Q28369150-4ABE8D41-9D62-4825-A371-981F55847449Q32052950-E7731B63-8543-4BB2-905E-5443F6B27DE0Q33409652-D8BF8127-6249-44AC-A91F-8305D9F92318Q33689514-BAEFDBE4-A279-4C7D-8571-1AE87FEEDFA6Q33697079-115B6DFF-02C6-4E11-BB59-D7ACAA9A76CCQ33929854-F42479C4-9DD6-4F4B-8231-2EF71EFC6B6CQ33977578-83140273-7A6C-4A54-95BF-663ABD4CA6DDQ33978188-C5954ECA-9D87-42ED-A8E1-82479F73D7D3Q33978764-B5DCE38F-9263-47F9-9C63-AAB3952F0D50Q33981387-C4F3E642-D8A5-4796-8D57-0B2DE71D9071Q33983629-2FA17174-CEF9-4CA6-9609-6CA2EDF1352DQ34108585-CC485B5C-393B-4EE9-871A-A9267B5504E6Q34108880-0A4F0D3C-B4CF-415D-8505-4EF67E0F48CCQ34113512-F7772A50-4EC7-448D-8EE2-7CF047D6E41BQ34113525-3B35F3F5-9808-4A73-979C-5B2D1A99374BQ34229980-4EF790EC-71F3-4618-A902-95489F6AA177Q34251910-9600D3E4-387C-4F48-B101-980747953A3AQ34680675-699732B9-A4EB-4419-8DE3-AD3DE99677C2Q35168703-A3109B4F-CA7E-4611-9F2B-0F79A4F3706FQ35372581-BA34C9FE-74C8-4B8E-B07E-C70A173707FBQ36276870-293DF59E-4A89-41E7-B2BB-5EF22A38543DQ36868273-C857473B-6C2C-404F-8128-97FA025365D8Q36909333-FC415FFB-3C49-482A-AF47-D52B11ABCBA9Q37016279-B03BC630-F9D5-48DF-ACB5-FE48596307AEQ37263800-FF9FB4C2-0052-477C-9639-A0DFDDA45207Q37613070-5B4BB4DD-F74B-4FD4-8CFB-DF4C95B2EAE3Q37935599-605038C2-EB85-4C42-8A40-04AC3F03E1CDQ37985070-FA9A8B1C-2929-46A0-9BD5-F201E2E515CEQ38040820-5B3CF214-395D-4A67-91CB-EECD03FB5E14Q38077678-09AC9FF3-508B-41A0-A5AF-22E49E60EC5FQ38193337-8EE941DD-358B-425E-8E01-3F7D2A4B4D39Q38572705-9EAB5291-53FD-4C75-8D63-9D74099E1509Q38872275-94520E7A-75A0-4190-8CD9-5DFD7BBBCBA1Q39472605-1084A480-0777-44D3-807D-D2314021F868Q39473015-91D11F89-93BF-4EE0-A303-E08D125813E3Q39473415-F98C1F6B-2FCD-4C3A-BEE8-06AE7C3D606BQ39476255-66A1388F-8219-4494-B57E-97A478756527Q40183751-B8AA4154-0544-4303-9937-89952B21F3D4Q40222438-BF1673CC-B421-4603-A395-146310CD3103Q41989595-2902C073-1A71-40EE-AEB0-4082D8571267
P2860
Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@ast
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@en
type
label
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@ast
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@en
prefLabel
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@ast
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@en
P2093
P2860
P356
P1476
Pharmacokinetics and safety of ...... ricin B (AmBisome) in rabbits.
@en
P2093
Amantea MA
Francis PA
Navarro EE
P2860
P304
P356
10.1128/AAC.38.4.713
P407
P577
1994-04-01T00:00:00Z